2025
Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.
Feder A, Brown O, Rutter S, Cahn L, Overbey J, Seeley S, Yu A, Bonanno P, Fremont R, Delgado A, Jha M, Costi S, Yehuda R, Schiller D, Pietrzak R, Charney D, Sloan D, Murrough J. Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial. The Journal Of Clinical Psychiatry 2025, 86 PMID: 40215385, DOI: 10.4088/jcp.24m15622.Peer-Reviewed Original ResearchConceptsChronic posttraumatic stress disorderPosttraumatic stress disorderKetamine infusionPosttraumatic stress disorder symptom severityClinician-Administered PTSD ScalePosttraumatic stress disorder symptomsDSM-5</i>Written Exposure TherapyOpen-label clinical trialIntravenous ketamine infusionSevere symptom levelsPTSD ScaleCAPS-5Exposure therapyStress disorderOpen-label trialSymptom levelsSymptom severityTreatment respondersPreliminary efficacyClinical trialsPreliminary findingsCombined treatmentLarge-scale randomized controlled trialsRandomized Controlled Trials
2023
Distinct neural networks predict cocaine versus cannabis treatment outcomes
Lichenstein S, Kohler R, Ye F, Potenza M, Kiluk B, Yip S. Distinct neural networks predict cocaine versus cannabis treatment outcomes. Molecular Psychiatry 2023, 28: 3365-3372. PMID: 37308679, PMCID: PMC10713861, DOI: 10.1038/s41380-023-02120-0.Peer-Reviewed Original ResearchConceptsConnectome-based predictive modelingCognitive behavior therapyCognitive behavioral therapySubstance use disordersCannabis abstinenceNeural mechanismsBehavior therapyDistinct neural networksComputer-based trainingCannabis use disorderFMRI scanningNeural predictorsStudy 1Study 2Treatment outcomesContingency managementPrior workComparison subjectsNetwork strengthUse disordersNovel treatment targetsAbstinenceIndependent samplesCocaine abstinenceTreatment respondersPercentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use
Loya J, Babuscio T, Nich C, Alessi S, Rash C, Kiluk B. Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use. Drug And Alcohol Dependence 2023, 248: 109947. PMID: 37276806, PMCID: PMC10498479, DOI: 10.1016/j.drugalcdep.2023.109947.Peer-Reviewed Original ResearchConceptsUrine drug screensClinical trialsMeaningful endpointsCocaine useLong-term clinical benefitBetter long-term outcomesDrug screensPsychosocial functioningNegative urine drug screensLong-term outcomesRandomized clinical trialsFuture clinical trialsBetter psychosocial functioningClinical benefitPharmacological treatmentContinuous abstinenceTreatment periodTreatment respondersSustained abstinenceSubstance useTrialsTreatmentMeaningful thresholdPooled datasetAbstinence
2020
Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up
Grilo CM, White MA, Ivezaj V, Gueorguieva R. Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up. Obesity 2020, 28: 2116-2124. PMID: 32985114, PMCID: PMC7644623, DOI: 10.1002/oby.22975.Peer-Reviewed Original ResearchConceptsBehavioral weight lossStepped careWeight lossWeight loss medicationsRandomized Controlled TrialsSignificant weight lossBinge-eating disorderBinge-eating frequencySignificant time effectBinge Eating DisorderCognitive behavioral therapyRemission rateControlled TrialsTreatment respondersLong-term effectsBehavioral therapyMixed modelsPatientsCareObesitySignificant reductionTreatmentMonthsPosttreatmentDisordersRandomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity
Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity. American Psychologist 2020, 75: 204-218. PMID: 32052995, PMCID: PMC7027689, DOI: 10.1037/amp0000534.Peer-Reviewed Original ResearchConceptsStepped-care treatmentCognitive behavioral therapyWeight loss medicationsBinge-eating disorderStepped careRemission rateWeight lossBehavioral weight lossSignificant weight lossBinge-eating frequencySignificant time effectControlled TrialsTreat analysisTreatment respondersMedicationsPlaceboMixed model analysisClinical practiceNonrespondersPatientsObesityBinge eatingCareMonthsTreatment
2019
Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling
Lichenstein SD, Scheinost D, Potenza MN, Carroll KM, Yip SW. Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling. Molecular Psychiatry 2019, 26: 4383-4393. PMID: 31719641, PMCID: PMC7214212, DOI: 10.1038/s41380-019-0586-y.Peer-Reviewed Original ResearchConceptsBrain statesDissociable neural substratesMultiple brain statesSubstance use outcomesHealthy comparison subjectsWhole-brain approachFMRI scanningFrontoparietal networkNeural substratesSubstance use treatmentNeural mechanismsDifferent brain statesFurther clinical relevanceDefault modeFMRI dataSubject replicationTreatment approachesReduced connectivityUse outcomesComparison subjectsNetwork strengthUse disordersSensory networksTreatment respondersSensory connectivityCaudate volume differences among treatment responders, non-responders and controls in children with obsessive–compulsive disorder
Vattimo E, Barros V, Requena G, Sato J, Fatori D, Miguel E, Shavitt R, Hoexter M, Batistuzzo M. Caudate volume differences among treatment responders, non-responders and controls in children with obsessive–compulsive disorder. European Child & Adolescent Psychiatry 2019, 28: 1607-1617. PMID: 30972581, DOI: 10.1007/s00787-019-01320-w.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderGroup cognitive behavioral therapyPediatric obsessive-compulsive disorderRight caudateTreatment responseCognitive behavioral therapyCaudate nucleusPossible neural substrateTreatment respondersGM volumeStructural magnetic resonance imagingNeural substratesPrevious evidenceNeurobiological underpinningsOrbitofrontal cortexAge-matched controlsTotal GM volumeMagnetic resonance imagingBrain structuresResonance imagingChildrenRespondersBonferroni correctionCaudatePatientsQuality of life and anxiety in children and adolescents in residential treatment facilities
Molinari A, Andrews J, Zaboski B, Kay B, Hamblin R, Gilbert A, Ramos A, Riemann B, Eken S, Nadeau J, Storch E. Quality of life and anxiety in children and adolescents in residential treatment facilities. Residential Treatment For Children & Youth 2019, 36: 220-234. DOI: 10.1080/0886571x.2018.1476201.Peer-Reviewed Original ResearchResidential treatment facilityAnxiety-related impairmentEffects of anxietyTreatment-seeking populationPotential moderator variablesSevere anxiety disorderChildren/youthQuality of lifeAnxiety disordersModeration effectDepression symptomologyModerator variablesPredictive utilityResearch implicationsAnxietyComorbid depressionTreatment respondersPoor QOLDepressionYouthMultimodal treatmentTreatment facilitiesAdolescentsSymptomologyParents
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesPredicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. Journal Of Vascular And Interventional Radiology 2018, 29: 850-857.e1. PMID: 29548875, PMCID: PMC5970021, DOI: 10.1016/j.jvir.2018.01.769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDoxorubicinEthiodized OilFemaleHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityTreatment OutcomeConceptsTransarterial chemoembolizationHepatocellular carcinomaTreatment responseLogistic regressionClinical patient dataPatient dataIntra-arterial therapyQuantitative European AssociationMagnetic resonance imagingLiver criteriaBaseline imagingClinical variablesTumor responseTherapeutic featuresTreatment respondersBaseline MRClinical informationImaging variablesChemoembolizationTherapeutic outcomesResonance imagingResponse criteriaEuropean AssociationPatientsMR imaging
2017
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed models
2016
NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER
Braga D, Abramovitch A, Fontenelle L, Ferrão Y, Gomes J, Vivan A, Ecker K, Bortoncello C, Mittelman A, Miguel E, Trentini C, Cordioli A. NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER. Depression And Anxiety 2016, 33: 848-861. PMID: 27100799, DOI: 10.1002/da.22509.Peer-Reviewed Original ResearchConceptsCognitive-behavioral group therapyObsessive-compulsive disorderBehavioral group therapyNeuropsychological test performanceTest performanceNeuropsychological domainsCBGT groupGroup therapyOCD patientsNeuropsychological outcome measuresNeuropsychological predictorsNeuropsychological functioningNeuropsychological measuresOCD symptomsNeurocognitive functionDepression symptomsTreatment respondersTreatment responseParticipantsAvailable researchInconsistent resultsDisordersPredictorsAnxietyMeasures
2013
Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)
Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, Ostacher M, Thase ME, Nierenberg A. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). The Pharmacogenomics Journal 2013, 14: 182-191. PMID: 23670706, DOI: 10.1038/tpj.2013.16.Peer-Reviewed Original ResearchConceptsPeripheral bloodTreatment responseLithium Treatment Moderate-Dose Use StudyLi respondersClinical responseTreatment initiationTreatment respondersMood symptomsLithium respondersEarly markerBipolar disorderRespondersBloodPatientsGene expression differencesSpecific roleSubjectsResponseBiochemical levelSymptomsDifferencesMonthsN-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapy
2010
Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis
Reyes MM, Panza KE, Martin A, Bloch MH. Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis. Journal Of The American Academy Of Child & Adolescent Psychiatry 2010, 50: 63-72. PMID: 21156271, PMCID: PMC3645909, DOI: 10.1016/j.jaac.2010.10.008.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsPlacebo-controlled trialTime-lag biasMajor depressive disorderYears of ageReuptake inhibitorsAntidepressant trialsPediatric depressionDepressive disorderTreatment respondersMAIN OUTCOMESystematic reviewMeta-analysisPositive findingsNegative findingsNegative trialsMedical literatureAntidepressantsTrialsPublication of findingsNegative resultsChild psychiatryEfficacyFindingsPublication time
2009
Intensive (Daily) Behavior Therapy for School Refusal: A Multiple Baseline Case Series
Tolin D, Whiting S, Maltby N, Diefenbach G, Lothstein M, Hardcastle S, Catalano A, Gray K. Intensive (Daily) Behavior Therapy for School Refusal: A Multiple Baseline Case Series. Cognitive And Behavioral Practice 2009, 16: 332-344. DOI: 10.1016/j.cbpra.2009.02.003.Peer-Reviewed Original ResearchCase seriesAcute treatment respondersIntensive behavior therapyMajority of casesCognitive behavioral therapyTreatment respondersSymptom presentationAssessment ScaleParent training sessionsTreatment elementsBehavior therapyMale adolescentsTherapyTreatmentTraining sessionsSchool refusal behaviorIntensive formatSchool refusalAdolescentsRefusal behaviorMeta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean change
2008
Effect of medication and psychotherapy on heart rate variability in panic disorder
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. Depression And Anxiety 2008, 26: 251-258. PMID: 18839407, DOI: 10.1002/da.20533.Peer-Reviewed Original ResearchConceptsHeart rate variabilityHeart rateRate variabilityLower heart rate variabilitySignificant clinical improvementWeeks of treatmentWeeks of CBTEffects of medicationPanic disorder patientsEffect of treatmentClinical improvementCardiac riskPD patientsCardiovascular diseaseTreatment respondersClinical measuresElevated riskDisorder patientsTreatment phasePatientsSymptom reductionPanic disorderHyperventilation challengeStatistical ManualSignificant decrease
2007
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2007, 32: 744-750. PMID: 18164528, DOI: 10.1016/j.pnpbp.2007.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsAripiprazoleBrief Psychiatric Rating ScaleDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleDrug EvaluationFemaleHumansMaleMiddle AgedPiperazinesProspective StudiesQuinolonesSocial BehaviorTime FactorsTreatment OutcomeConceptsHDRS-24Adjunctive treatmentSNRI medicationsUnipolar depressionCurrent episodeWeek open label studyTreatment-resistant major depressionCurrent DSM-IV diagnosisEffectiveness of aripiprazoleRefractory unipolar depressionOpen-label studyEffective adjunctive treatmentDSM-IV diagnosisFluoxetine equivalentsSNRI treatmentWeek 12Baseline severityMean doseMajor depressionTreatment respondersSide effectsSSRIsMaximum doseAripiprazoleMedications
2005
Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleTreatment-resistant OCD patientsAddition of riluzolePractical clinical benefitOpen-label trialGlutamate-modulating agentsSerious adverse effectsHamilton Depression InventoryAnxiety Inventory scoresObsessive Compulsive ScaleMost patientsStandard therapyGlutamatergic dysfunctionAugmentation therapyClinical benefitPrimary diagnosisStandard treatmentCorticostriatal pathwayTreatment respondersRiluzolePatientsDepression Inventory
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply